Matthew Lalli (He/him)

Matthew Lalli is a highly creative and interdisciplinary scientist with 14 years of expertise in applying functional genomics approaches to understand neurological disorders.

After completing his Ph.D., Matthew joined Washington University in St. Louis as a Postdoctoral Scholar in the department of Genetics in 2015. There he combined pluripotent stem cells, single-cell readouts, and CRISPR/Cas9 technology to interrogate disease mechanisms at high-throughput. In 2020, this work continued at the Seaver Autism Center at Icahn School of Medicine where Matthew served as a junior faculty member. During this time, Matthew was the recipient of several awards and grants including the NARSAD Young Investigator award and an NIH R21.

Since November 2023, Matthew has been employed as a Senior Scientist at Lyterian Therapeutics integrating functional genomics approaches into the drug discovery pipeline. Matthew is committed to delivering a positive impact to society through research and scientific outreach and is enthusiastic about using new technologies to improve human health.